Last10K.com

Genmark Diagnostics, Inc. (GNMK) SEC Filing 8-K Material Event for the period ending Monday, May 4, 2020

Genmark Diagnostics, Inc.

CIK: 1487371 Ticker: GNMK

Exhibit 99.1

May 4, 2020

GenMark Diagnostics Reports First Quarter 2020 Results

CARLSBAD, Calif - GenMark Diagnostics, Inc. ("GenMark" or the "Company") (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended March 31, 2020.

First Quarter 2020 Financial Highlights
Total revenue of $38.7 million, an increase of 80% over the first quarter of 2019
ePlex revenue of $34.3 million, an increase of approximately 119% over the first quarter of 2019
Gross margin of 42%, compared to 27% in the first quarter of 2019

Recent Operational Highlights
Placed 54 net new ePlex analyzers in the first quarter of 2020, expanding the global installed base to 581 as of March 31, 2020
Increased average annuity per ePlex analyzer to approximately $214,000, up 29% versus the first quarter of 2019
Granted Emergency Use Authorization (EUA) for ePlex COVID-19 test on March 19th
Awarded $749,000 in BARDA funding to develop ePlex RP2 Panel
Appointed Scott Mendel as CEO, effective May 2, 2020

“Our 2020 key priorities of strong revenue growth, margin expansion, and technology development remain intact despite the COVID-19 pandemic,” said Scott Mendel, President and Chief Executive Officer. “We made significant strides on all fronts during the first quarter by delivering molecular diagnostic solutions that enable better patient outcomes for critically ill patients.”

First Quarter Financial Results
Revenue was $38.7 million in the first quarter of 2020, an increase of 80% versus $21.5 million in the first quarter of 2019.

Gross profit was $16.2 million, or approximately 42% of revenue, compared with $5.9 million, or 27% of revenue in the same period of 2019.

Operating expenses for the first quarter of 2020 were $21.2 million compared to $16.8 million in the same period of 2019. Approximately $4.6 million of this increase resulted from nonrecurring charges associated with organizational changes including the departure of the former CEO.

Loss per share was $0.12 for the first quarter of 2020, compared to a $0.21 loss per share in the first quarter of 2019. Loss per share for the first quarter of 2020 after non-recurring charges was $0.04 compared to $0.21 in the first quarter of 2019.

Cash and investments were $47.1 million as of March 31, 2020.

Guidance for Full Year 2020
GenMark is increasing total revenue expectations for the full year 2020 to $120 to $130 million.

The Company now expects global ePlex placements to range from 175 to 200 net new analyzers with an annuity per analyzer remaining at $130,000 to $135,000.

Gross margin guidance is increasing to the 38% to 40% range. Operating expense expectations continue to be approximately $65 million to $70 million. Cash usage in operations is projected to be in the range of $5 million to $10 million.

Webcast and Conference Call Information
GenMark will be hosting a conference call to discuss first quarter results in further detail on Monday, May 4, 2020 starting at 4:30 p.m. ET. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 2190875 approximately five minutes prior to the start time.





About GenMark Diagnostics
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections.  For more information, visit www.genmarkdx.com.

Safe Harbor Statement
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect the Company’s future operating results and financial position. Such statements, including, but not limited to, those regarding its future financial performance, achievement of profitability targets, plans and objectives of management, the timely and effective commercialization and clinical impact of the Company’s ePlex system, and the impact of the COVID-19 pandemic on the Company's business are all subject to risks and uncertainties that could cause actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, GenMark’s ability to successfully commercialize the Company's ePlex system and its related test menu in a timely manner, constraints or inefficiencies caused by unanticipated acceleration and deceleration of customer demand, the Company’s ability to successfully expand sales of its product offerings outside the United States, and third-party payor reimbursement to its customers , and the effects and potential effects of the COVID-19 pandemic on the Company’s business, cash flow, liquidity and results of operations and legislative or regulatory developments affecting the Company’s industry, as well as other risks and uncertainties described under the “Risk Factors” in GenMark’s public filings with the Securities and Exchange Commission. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

Investor Relations Contact    
Leigh Salvo    
(415) 937-5404  





GENMARK DIAGNOSTICS, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)
March 31,
2020
December 31,
2019
ASSETS:
Current Assets:
Cash and cash equivalents$26,261  $44,360  
Short-term marketable securities20,805  9,100  
Accounts receivable, net of allowances of $405 and $376, respectively25,721  16,759  
Inventories, net9,927  11,301  
Prepaid expenses and other current assets1,800  1,877  
Total current assets84,514  83,397  
Property and equipment, net19,580  20,419  
Intangible assets, net1,284  1,432  
Restricted cash758  758  
Noncurrent operating lease right-of-use assets4,511  4,642  
Other long-term assets945  825  
Total assets$111,592  $111,473  
LIABILITIES AND STOCKHOLDERS' EQUITY:
Current liabilities:
Accounts payable$10,333  $12,249  
Accrued compensation7,396  7,493  
Current portion of long-term debt3,431  —  
Current operating lease liability1,856  1,842  
Other current liabilities3,793  2,732  
Total current liabilities26,809  24,316  
Long-term debt66,210  69,145  
Noncurrent operating lease liability5,513  5,796  
Other noncurrent liabilities57  53  
Total liabilities98,589  99,310  
Stockholders' equity:
Preferred stock, $0.0001 par value; 5,000 authorized, none issued—  —  
Common stock, $0.0001 par value; 100,000 authorized; 61,333 and 60,255 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively  
Additional paid-in capital534,177  526,294  
Accumulated deficit(521,241) (514,233) 
Accumulated other comprehensive income61  96  
Total stockholders’ equity13,003  12,163  
Total liabilities and stockholders’ equity$111,592  $111,473  








GENMARK DIAGNOSTICS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands, except per share data)

Three Months Ended
March 31,
20202019
Revenue:
Product revenue$38,685  $21,371  
Other revenue57  162  
Total revenue38,742  21,533  
Cost of revenue
22,590  15,670  
Gross profit16,152  5,863  
Operating expenses:
Sales and marketing6,140  5,909  
General and administrative8,938  4,521  
Research and development6,079  6,343  
Total operating expenses21,157  16,773  
Loss from operations(5,005) (10,910) 
Other income (expense):
Interest income132  133  
Interest expense(2,091) (1,276) 
Other expense
(29) (11) 
Total other expense(1,988) (1,154) 
Loss before provision for income taxes(6,993) (12,064) 
Income tax expense15  16  
Net loss$(7,008) $(12,080) 
Net loss per share, basic and diluted$(0.12) $(0.21) 
Weighted average number of shares outstanding, basic and diluted60,666  56,581  
Other comprehensive loss:
Net loss$(7,008) $(12,080) 
Other comprehensive income (loss):
Foreign currency translation adjustments, net of tax(39) (6) 
Net unrealized gains on marketable securities, net of tax  
Total other comprehensive income(35) (4) 
Total comprehensive loss$(7,043) $(12,084) 













GENMARK DIAGNOSTICS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
Three Months Ended
March 31,
20202019
Operating activities:
Net loss$(7,008) $(12,080) 
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization1,799  1,812  
Net amortization (accretion) of premiums/discounts on investments12  (21) 
Amortization of deferred debt issuance costs 596  366  
Stock-based compensation5,620  2,544  
Provision for bad debt29  —  
Non-cash inventory adjustments434  634  
Other non-cash adjustments(79) (16) 
Changes in operating assets and liabilities:
Accounts receivable(8,979) 2,355  
Inventories920  (131) 
Prepaid expenses and other assets 51  —  
Accounts payable(1,558) (1,043) 
Accrued compensation(550) (2,475) 
Other current and non-current liabilities1,108  (126) 
Net cash used in operating activities(7,605) (8,181) 
Investing activities:
Purchases of property and equipment(952) (333) 
Purchases of marketable securities(14,613) (12,014) 
Maturities of marketable securities2,900  7,800  
Net cash used in investing activities(12,665) (4,547) 
Financing activities:
Proceeds from issuance of common stock, net of offering costs2,160  —  
Principal repayment of borrowings(23) (35,116) 
Proceeds from borrowings—  50,000  
Payments associated with debt issuance(100) (3,588) 
Proceeds from stock option exercises103  430  
Net cash provided by financing activities2,140  11,726  
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
31  20  
Net decrease in cash, cash equivalents, and restricted cash
(18,099) (982) 
Cash, cash equivalents, and restricted cash at beginning of year
45,118  37,044  
Cash, cash equivalents, and restricted cash at end of period
$27,019  $36,062  
Non-cash investing and financing activities:
Transfer of systems to property and equipment from inventory$21  $351  
Property and equipment included in accounts payable$874  $36  
Supplemental cash flow information:
Cash paid for income taxes, net $19  $44  
Cash paid for interest$1,541  $761  







GENMARK DIAGNOSTICS, INC.
UNAUDITED RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(In thousands)

Three Months Ended
March 31,
20202019
GAAP net loss$(7,008) $(12,080) 
Nonrecurring charges:
Severance payments and stock-based compensation resulting from reorganization1
566  —  
Severance payments and stock-based compensation due to our former President and CEO upon his departure from the Company2
4,047  —  
Total nonrecurring charges4,613  —  
Adjusted non-GAAP net loss$(2,395) $(12,080) 
GAAP and non-GAAP weighted average shares outstanding - basic and diluted60,666  56,581  
GAAP net loss per share - basic and diluted$(0.12) $(0.21) 
Nonrecurring charges:
Severance payments and stock-based compensation resulting from reorganization0.01  —  
Severance payments and stock-based compensation due to our former President and CEO upon his departure from the Company0.07  —  
Total nonrecurring charges0.08  —  
Adjusted non-GAAP net loss per share - basic and diluted$(0.04) $(0.21) 
1 Severance payments and stock-based compensation expense resulting from the elimination of certain positions within the Company. Stock-based compensation expense resulted from the acceleration of the vesting of restricted stock units awarded to certain individuals.
2 Severance payments and stock-based compensation expense resulting from the departure of the Company's former President and CEO. The Company will be making a $1 million severance payment to the Company's former President and CEO on October 1, 2020 and will be providing reimbursement for group health insurance premium payments pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended ("COBRA") for 1 year following the separation date. The Company recognized $3 million in stock-based compensation expense resulting from the acceleration of the vesting of the outstanding unvested portion of restricted stock units and market-based stock units.

Use of Non-GAAP Financial Information
In addition to results reported under GAAP, we provide certain non-GAAP financial measures consisting of adjusted non-GAAP net loss and adjusted non-GAAP basic and diluted net loss per share. Non-GAAP net loss consists of the net loss reported in our Unaudited Condensed Consolidated Statement of Comprehensive Loss adjusted for nonrecurring severance payments and stock-based compensation expense from the elimination of certain positions and the departure of our former President and CEO. Adjusted non-GAAP basic and diluted net loss per share reflects the net loss per share reported in our Unaudited Condensed Consolidated Statement of Comprehensive Loss adjusted for the loss per share resulting from nonrecurring severance payments and stock-based compensation expense from the elimination of certain positions and the departure of our former President and CEO.

We believe that use of these non-GAAP financial measures can assist investors in understanding the results from our core operations by providing additional insight into the impact of nonrecurring activities on our GAAP financial measures. We believe that the use of these non-GAAP financial measures enhances the comparability of our current period results to our historical Unaudited Condensed Consolidated Financial Statements, as well as to the results of other public companies.

The use of these non-GAAP financial measures are not measurements of financial performance under GAAP and have been included solely for informational and comparative purposes. Other companies may define these non-GAAP financial measures differently and, as a result, our non-GAAP financial measures may not be directly comparable to the non-GAAP measures of other companies. We reconciled non-GAAP net loss and adjusted non-GAAP basic and diluted net loss per share to GAAP net




loss and GAAP net loss per share, respectively, which we believe to be the most directly comparable GAAP financial measures. Reconciliations of non-GAAP and GAAP financial measures should be considered together with our Unaudited Condensed Consolidated Financial Statements.


View differences made from one to another to evaluate Genmark Diagnostics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Genmark Diagnostics, Inc..

Continue

Assess how Genmark Diagnostics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Genmark Diagnostics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Material Contracts, Statements, Certifications & more

Genmark Diagnostics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: GNMK
CIK: 1487371
Form Type: 8-K Corporate News
Accession Number: 0001487371-20-000132
Submitted to the SEC: Mon May 04 2020 4:10:05 PM EST
Accepted by the SEC: Mon May 04 2020
Period: Monday, May 4, 2020
Industry: Surgical And Medical Instruments And Apparatus
Events:
  1. Earnings Release
  2. Financial Exhibit

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/gnmk/0001487371-20-000132.htm